JPMorgan Chase & Co. Issues Positive Forecast for GE HealthCare Technologies (NASDAQ:GEHC) Stock Price

Key Points

• JPMorgan raised its GE HealthCare price target from $70 to $80 while maintaining a neutral rating, implying about 4.7% upside. The broader analyst consensus is “Moderate Buy,” with an average price target of $80.57.
• GE HealthCare exceeded quarterly expectations, reporting $1.34 adjusted EPS versus the $1.20 consensus and $5.51 billion in revenue, up 7.2% year over year.
• Investor sentiment has improved as management raised its 2026 outlook, citing broad-based demand, margin expansion and growth initiatives including Pharmaceutical Diagnostics, Flyrcado and the SOFIE acquisition.

GE HealthCare Technologies (NASDAQ:GEHC - Get Free Report) had its price objective increased by JPMorgan Chase & Co. from $70.00 to $80.00 in a research report issued on Thursday, Benzinga reports. The brokerage currently has a "neutral" rating on the stock. JPMorgan Chase & Co.'s target price would suggest a potential upside of 4.68% from the stock's current price.

Several other equities research analysts have also recently weighed in on GEHC. Citigroup upped their price target on GE HealthCare Technologies from $71.00 to $79.00 and gave the stock a "neutral" rating in a research note on Thursday. Wolfe Research initiated coverage on GE HealthCare Technologies in a research report on Tuesday, October 20th. They set a "peer perform" rating for the company. Bank of America reiterated a "neutral" rating on shares of GE HealthCare Technologies in a research note on Thursday. BMO Capital Markets began coverage on shares of GE HealthCare Technologies in a research report on Wednesday, July 8th. They set a "market perform" rating and a $70.00 price target for the company. Finally, Wells Fargo & Company boosted their price objective on shares of GE HealthCare Technologies from $75.00 to $85.00 and gave the stock an "overweight" rating in a research note on Thursday, July 30th. Twelve investment analysts have rated the stock with a Buy rating and eleven have assigned a Hold rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $80.57.

GE HealthCare Technologies Trading Up 0.8%

Shares of NASDAQ:GEHC traded up $0.60 on Thursday, reaching $76.42. 4,639,326 shares of the company traded hands, compared to its average volume of 4,242,644. The stock has a market capitalization of $34.52 billion, a P/E ratio of 17.53, a price-to-earnings-growth ratio of 1.89 and a beta of 0.73. The business's 50-day simple moving average is $68.37 and its 200 day simple moving average is $70.17. The company has a current ratio of 1.26, a quick ratio of 0.97 and a debt-to-equity ratio of 0.92. GE HealthCare Technologies has a 52 week low of $58.75 and a 52 week high of $89.77.

GE HealthCare Technologies (NASDAQ:GEHC - Get Free Report) last released its quarterly earnings data on Wednesday, October 28th. The company reported $1.34 earnings per share for the quarter, beating analysts' consensus estimates of $1.20 by $0.14. The firm had revenue of $5.51 billion during the quarter, compared to analyst estimates of $5.35 billion. GE HealthCare Technologies had a return on equity of 20.12% and a net margin of 9.33%. The business's quarterly revenue was up 7.2% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.07 earnings per share. As a group, equities analysts anticipate that GE HealthCare Technologies will post 4.93 EPS for the current fiscal year.

Institutional Trading of GE HealthCare Technologies

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. NBH Bank bought a new position in shares of GE HealthCare Technologies in the second quarter worth $26,000. Physician Wealth Advisors Inc. boosted its holdings in shares of GE HealthCare Technologies by 60.4% in the first quarter. Physician Wealth Advisors Inc. now owns 433 shares of the company's stock valued at $31,000 after acquiring an additional 163 shares in the last quarter. Global Assets Advisory LLC bought a new position in shares of GE HealthCare Technologies in the first quarter valued at approximately $37,000. Fortitude Family Office LLC increased its stake in shares of GE HealthCare Technologies by 249.1% during the third quarter. Fortitude Family Office LLC now owns 597 shares of the company's stock valued at $39,000 after acquiring an additional 426 shares during the period. Finally, Aberdeen Wealth Management LLC acquired a new position in shares of GE HealthCare Technologies during the second quarter valued at approximately $44,000. 82.06% of the stock is owned by hedge funds and other institutional investors.

Trending Headlines about GE HealthCare Technologies

Here are the key news stories impacting GE HealthCare Technologies this week:

• Positive Sentiment: Quarterly earnings beat expectations: GEHC reported third-quarter adjusted EPS of $1.34, versus the $1.20–$1.21 analyst consensus, while revenue of $5.51 billion exceeded estimates of approximately $5.35 billion and increased 7.2% year over year. GE HealthCare reports third quarter 2026 financial results
• Positive Sentiment: Guidance was raised: Management increased its 2026 outlook, including organic revenue growth of about 4%, adjusted EPS of $4.95–$5.05 and free cash flow of at least $1.6 billion. Broad-based demand, stronger margins and healthy hospital spending contributed to the upgrade. GE HealthCare lifts forecasts on healthy hospital spending
• Positive Sentiment: Growth initiatives strengthen the outlook: Analysts highlighted 6.2% organic growth, margin expansion, Pharmaceutical Diagnostics, the Flyrcado product and the SOFIE acquisition as potential drivers of future revenue and radiopharmaceutical growth. GE HealthCare Q3 broad-based growth makes the bull case more compelling
• Positive Sentiment: Analyst targets moved higher: Mizuho raised its price target to $90 from $85, BNP Paribas increased its target to $100 from $96, and BTIG lifted its target to $83 from $75 while maintaining a buy rating. Mizuho Securities adjusts GE HealthCare price target
• Neutral Sentiment: A comparison with Haemonetics discusses GEHC’s relative value appeal among medical-products stocks, but does not introduce a material new company-specific catalyst. GEHC versus HAE value comparison
• Negative Sentiment: Jeannette Bankes, president and CEO of Patient Care Solutions, is leaving to become CEO of another company. The leadership transition is a modest uncertainty, although it was overshadowed by the earnings beat. GE HealthCare shares rise on higher results and outlook upgrade

About GE HealthCare Technologies

GE HealthCare Technologies Inc is a global medical technology company that develops and provides products, services and digital solutions for healthcare providers. Its offerings are designed to support the diagnosis, treatment and monitoring of patients across hospitals, outpatient facilities, imaging centers and other care settings.

The company's portfolio includes medical imaging systems such as computed tomography, magnetic resonance imaging, molecular imaging, surgical imaging and X-ray equipment.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.